Other Clinical Trial - A Non-Interventional Study of Clinical

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Primary Objective(s): - To describe the demographic characteristics of people living with FOP - To describe the prevalence of clinical characteristics of interest in people living with FOP - To describe the use of key medications in people living with FOP - To estimate the crude mortality rate among people with FOP

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05090891` - To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva	Phase 2
Active, not recruiting	`NCT05027802` - A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.	Phase 3
Recruiting	`NCT02745158` - The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry	N/A

NCT number	NCT06064656
Study type	Observational
Source	Regeneron Pharmaceuticals
Contact
Status	Completed
Phase
Start date	June 29, 2023
Completion date	September 29, 2023

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms